Rep. Andrew Garbarino (R., N.Y.), chairman of the House Homeland Security Committee's subcommittee on cybersecurity and infrastructure protection, said the change in administration and leadership at ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...

Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...

H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the ...

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) was the target of some unusual options trading on Monday. Investors purchased 5,081 call options on the stock. This represents an increase ...

Fintel reports that on March 10, 2025, Lake Street downgraded their outlook for Checkpoint Therapeutics (NasdaqCM:CKPT) from ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical ...

Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.

Following the market opening Monday, the Dow traded down 1.01% to 42,370.97 while the NASDAQ dipped 3.21% to 17,612.44. The S ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...